Skip to main content
Health Care CostsDigital healthBehavioralBehavioral

What this study is

Expanded availability of virtual care encounters in Primary Care provides new opportunities to improve Veterans' outcomes by aligning encounter modalities with their needs and preferences. Yet, Veterans and their Primary Care physicians (PCPs) lack personalized information about the benefits and costs of different Primary Care modalities that is needed to maximize the value of Primary Care encounters. To address this problem, in this study the investigators will use surveys and interviews to identify what Veterans and PCPs perceive to be the benefits and optimal uses of different Primary Care encounter modalities. They will then supplement their existing system for communicating encounter costs to Veterans and PCPs with new interactive messaging about benefits and optimal uses of different encounter modalities. Finally, this novel Advancing Decisions about Virtual Service Encounters (ADViSE) intervention will be optimized through user-centered refinement before evaluating its effects on Veteran-centered outcomes, use of virtual care, and intermediate health outcomes in a randomized controlled trial (RCT).

What's being tested

  • Clinician Coaching Sessions

    Intervention · BEHAVIORAL

    PCPs will receive interactive coaching sessions from a Clinician Coach 2 months into the intervention period and again at 4 months into the intervention period.

  • Personalized text messages to patients

    Intervention · OTHER

    Drawing upon a library of messages that have previously been developed and refined, Veterans will receive 6 months of optimized text messages. The frequency of text messages will be determined based on feedback from Veterans in earlier phases of the research.

Study details

Official title
Advancing Decisions About Virtual Service Encounters (ADViSE)
Sponsor
VA Office of Research and Development
Conditions
Health Care Costs · Delivery of Health Care
Enrolling
600 people
Starts
2026-04-01
Est. completion
2028-06-30
Design
Open-label, randomized, crossover
Record
View on ClinicalTrials.gov ↗